We don’t support this browser anymore.
This means our website may not look and work as you would expect. Read more about browsers and how to update them here.

Biocryst Pharmaceuticals Inc (BCRX) Com Stk USD 0.01

Sell:$7.70 Buy:$7.71 Change: $0.05 (0.65%)
NASDAQ:0.05%
Market closed |  Prices as at close on 26 December 2024 | Switch to live prices |
Sell:$7.70
Buy:$7.71
Change: $0.05 (0.65%)
Deal now Deal for just £11.95 per trade in a Stocks and Shares ISA, Lifetime ISA , SIPP or Fund and Share Account
Deal now
Market closed |  Prices as at close on 26 December 2024 | Switch to live prices |
Sell:$7.70
Buy:$7.71
Change: $0.05 (0.65%)
Market closed |  Prices as at close on 26 December 2024 | Switch to live prices |
Deal now Deal for just £11.95 per trade in a Stocks and Shares ISA, Lifetime ISA , SIPP or Fund and Share Account
Deal now
The selling price currently displayed is higher than the buying price. This can occur temporarily for a variety of reasons; shortly before the market opens, after the market closes or because of extraordinary price volatility during the trading day.

Business summary

BioCryst Pharmaceuticals, Inc. is a biotechnology company focused on improving the lives of people living with complement-mediated and other rare diseases. The Company leverages its expertise in designing to develop first-in-class oral small-molecule and protein therapeutics to target difficult-to-treat diseases. Its marketed products include oral, once-daily ORLADEYO for the prevention of hereditary angioedema (HAE) attacks and RAPIVAB (peramivir injection) for the treatment of acute uncomplicated influenza in the United States. Its other products and product candidates include BCX10013, RAPIACTA (peramivir injection), PERAMIFLU (peramivir injection), and early-stage discovery programs. BCX10013, is a potent and specific Factor D inhibitor. RAPIACTA focuses on uncomplicated seasonal influenza. RAPIVAB (peramivir injection) is approved in the United States for the treatment of acute uncomplicated influenza for patients six months and older.

Contact details

Address:
4505 Emperor Blvd Ste 200
DURHAM
27703-8457
United States
Telephone:
+1 (919) 8591302
Website:
https://www.biocryst.com/

Important dates

Future events
There are no future events available.
Past events
There are no past events available.

General stock information

Short code:
BCRX
ISIN:
US09058V1035
Market cap:
$1.59 billion
Shares in issue:
207.13 million
Sector:
Biotechnology
Exchange:
NASDAQ
Country:
United States
Currency:
US dollar
Indices:
NASDAQ Comb. Composite

Key personnel

  • Jon Stonehouse
    President, Chief Executive Officer, Director
  • Anthony Doyle
    Chief Financial Officer
  • Donald Fong
    Chief Medical Officer
  • Charles Gayer
    Chief Commercial Officer
  • William Sheridan
    Chief Development Officer
  • Helen Thackray
    Chief Research & Development Officer
  • Alane Barnes
    Chief Legal Officer, Corporate Secretary

Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Business summary, contact details and key personnel provided by Thomson Reuters. Important dates provided by Digital Look Ltd. General stock information provided by Reuters.

Options

Share

The London Stock Exchange does not disclose whether a trade is a buy or a sell so this data is estimated based on the trade price received and the LSE-quoted mid-price at the point the trade is placed. It should only be considered an indication and not a recommendation.

Trades priced above the mid-price at the time the trade is placed are labelled as a buy; those priced below the mid-price are sells; and those priced close to the mid-price or declared late are labelled 'N/A'.